FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

Speaking Engagement
On June 17, 2013, the Supreme Court decided Federal Trade Commission v. Actavis, Inc., which resolved a circuit split over the appropriate antitrust standard to apply when evaluating "reverse payment" Hatch-Waxman patent litigation settlements. This decision has significant consequences for settlements in branded vs. generic abbreviated new drug application (ANDA) litigation in the pharmaceutical industry.

WilmerHale Partner Mark Ford is a featured speaker at this Boston Bar Association event, and will be presenting an antitrust analysis of reverse payment settlements in Hatch-Waxman cases.

Read More About the Event

Speakers

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.